{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T13:30:43Z","timestamp":1769607043048,"version":"3.49.0"},"reference-count":50,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T00:00:00Z","timestamp":1739059200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To summarise the efficacy and toxicity of salvage low\u2010dose\u2010rate brachytherapy (LDR\u2010BT) and compare these findings with the published data on salvage high\u2010dose\u2010rate brachytherapy (HDR\u2010BT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We reviewed PubMed and EMBASE for studies published up to May 2024, mainly focusing on recurrence\u2010free survival (RFS) with salvage LDR\u2010BT across subgroups. We also compared RFS and adverse events with HDR\u2010BT as a secondary objective. We reconstructed survival curves using a semi\u2010automated tool called WebPlotDigitizer, along with a new shiny application integrated with R.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 31 studies (891 patients) met the inclusion criteria for salvage LDR\u2010BT. The median RFS of patients treated with salvage LDR\u2010BT was 131.6\u2009months, with 2\u2010, 3\u2010 and 5\u2010year rates of 84.6%, 74.3% and 63.5%. Lower median age (65\u201370\u2009years vs 72.3\u201375\u2009years, hazard ratio [HR] 0.50, 95% confidence interval [CI] 0.35\u20130.70;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001) and higher adjuvant androgen deprivation therapy (ADT) proportion (83.8%\u2013100% vs 0%\u201347%, HR 0.60, 95% CI 0.55\u20130.65;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.036) were positive RFS factors. Compared to HDR\u2010BT, salvage LDR\u2010BT demonstrated improved RFS for all patients (HR 0.67, 95% CI 0.55\u20130.81;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001). Specifically, salvage LDR\u2010BT exhibited superior RFS (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05) for patients with a median age \u226470\u2009years at recurrence, a median time from primary treatment to salvage therapy (TPTS) of \u226570\u2009months, a median pre\u2010salvage prostate\u2010specific antigen level of \u22655\u2009ng\/mL, and a proportion of adjuvant ADT of \u226553%, compared to HDR\u2010BT. However, LDR\u2010BT was associated with a higher rate of severe gastrointestinal (GI; 3.5% vs 0.3%, odds ratio [OR] 0.08, 95% CI 0.03\u20130.28;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001) and genitourinary (GU) toxicities (12.7% vs 5.8%, OR 0.42, 95% CI 0.30\u20130.60;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001) compared to HDR\u2010BT.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In specific cohorts, salvage LDR\u2010BT appears to yield superior RFS but entails a higher incidence of severe GI\/GU toxicities compared to HDR\u2010BT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bju.16639","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T20:24:36Z","timestamp":1739219076000},"page":"940-952","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Salvage low\u2010dose vs high\u2010dose brachytherapy for radio\u2010recurrent prostate cancer"],"prefix":"10.1111","volume":"135","author":[{"given":"Shaoqin","family":"Xie","sequence":"first","affiliation":[{"name":"Department of Urology Shaoxing People's Hospital  Shaoxing Zhejiang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3415-779X","authenticated-orcid":false,"given":"Jianjiang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy Shaoxing People's Hospital  Shaoxing Zhejiang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Urology Shaoxing People's Hospital  Shaoxing Zhejiang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huali","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Urology Shaoxing People's Hospital  Shaoxing Zhejiang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiajing","family":"Ni","sequence":"additional","affiliation":[{"name":"Department of Urology Shaoxing People's Hospital  Shaoxing Zhejiang China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,2,9]]},"reference":[{"key":"e_1_2_10_2_1","first-page":"1288","article-title":"NCCN guidelines\u00ae insights: prostate cancer, version 1.2023","volume":"20","author":"Schaeffer EM","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000000110"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.04.076"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(02)02977-2"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2005.06.002"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2013.12.014"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003892"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.11.010"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-024-02205-x"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2006.04.029"},{"key":"e_1_2_10_12_1","first-page":"1035","article-title":"Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel","volume":"37","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-021-01308-8"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/2049-3258-72-39"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.5114\/jcb.2023.126618"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2021.10.138"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2018.09.039"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2020.10.021"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.14151"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpor.2020.06.010"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2019.09.006"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.5114\/jcb.2017.69235"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brachy.2017.07.013"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brachy.2016.12.011"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/1179554917738765"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/9561494"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.5114\/jcb.2016.60452"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brachy.2015.01.002"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brachy.2013.10.012"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.12373"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2014.06.013"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.5114\/jcb.2014.45134"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1159\/000346322"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2012.04.028"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brachy.2009.06.007"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.06.061"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2009.08445.x"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brachy.2007.11.002"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2006.07.008"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22934"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1177\/153303460300200409"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(99)00241-1"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(98)00492-0"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2388(199711\/12)13:6<406::AID-SSU4>3.0.CO;2-E"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.2990230403"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)39560-5"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041180"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24511"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.10.014"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.07.014"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.07.012"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.16639","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T14:19:49Z","timestamp":1761747589000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.16639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,9]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1111\/bju.16639"],"URL":"https:\/\/doi.org\/10.1111\/bju.16639","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,9]]},"assertion":[{"value":"2025-02-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}